Gastrointestinal Cancer

Mohamed E. Salem, MD, highlights ongoing research efforts to potentially improve survival in patients with metastatic colorectal cancer.

A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.

In recent years, pancreatic has passed breast cancer as the third leading cause of cancer death in the United States, and by 2030 it could be the leading cause.

Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist at Moffitt Cancer Center, discusses the use of immunotherapy in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm.

Amit Mahipal, MBBS, professor of medicine, Mayo Clinic, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting

Rutika Mehta, MD, MPH, discusses the current gastric cancer treatment landscape and sheds light on how emerging therapies could impact the paradigm.